The Fat We Stopped Eating (And Why It Might Matter More Than We Thought)
We age because our cells do. Over time, cell membranes get more fragile, mitochondria get less efficient, and the small, daily wear that our bodies used to shrug off starts to leave a mark. Most of what we know about slowing that process comes down to the basics I talk about with patients every week: eat real food, move your body, sleep, and keep your toxic load low. That advice still holds.
But there's a newer piece of the puzzle that has caught my attention, and it's a strange one. It starts with dolphins.
A discovery that came from the wrong species
In the early 2000s, a Navy veterinary epidemiologist named Dr. Stephanie Venn-Watson noticed something odd. The dolphins in the Navy's care were living far longer than dolphins in the wild, and some of the older ones were developing conditions that looked a lot like ours: high cholesterol, fatty liver, even changes resembling Alzheimer's. When her team went looking for what separated the healthier-aging dolphins from the rest, one molecule kept surfacing. A saturated fat called pentadecanoic acid, or C15:0.
Her group eventually published the idea that C15:0 might be an essential fatty acid, meaning a nutrient our bodies can't make in adequate amounts and have to get from food [1]. If that holds up, it would be the first essential fatty acid identified since the omega-3s, nearly a century ago. That's a big claim, and I'll come back to how settled it actually is. But the early work was interesting enough that researchers kept pulling the thread.
What C15:0 seems to do in the body
The part I find most compelling isn't the dolphin story, it's the cell biology. In lab studies comparing C15:0 against some of the best-known longevity compounds, including rapamycin, metformin, and acarbose, C15:0 showed a surprisingly broad range of activity. It was active in 10 of the 12 human cell systems tested, with anti-inflammatory and anti-fibrotic effects that overlapped heavily with rapamycin [2].
Mechanistically, a few things stand out. C15:0 appears to activate AMPK, the enzyme your cells lean on to sense energy and stay metabolically flexible, while dialing down mTOR, a pathway tied to growth and aging [2]. It also slots neatly into cell membranes, where it seems to make them sturdier and less prone to the kind of oxidative damage that ages red blood cells before their time [2]. Sturdier membranes, calmer inflammation, better-running mitochondria. For anyone working in this space, that's a familiar wish list.
The deficiency nobody was looking for
Here's where it gets practical. C15:0 lives mostly in whole-fat dairy and a few types of fish. Over the last few decades, we collectively did two things: we backed away from full-fat dairy on the assumption that all saturated fat was bad, and we shifted cattle from grass to grain, which lowered the C15:0 in the milk that remained.
The result, according to Venn-Watson's more recent work, is a genuine nutritional gap. She's proposed that low C15:0 levels drive what she calls Cellular Fragility Syndrome, a deficiency state she estimates may affect as many as one in three people worldwide [3]. The symptoms she describes are frustratingly vague on their own: fatigue, poor sleep, slower recovery, but they map onto a measurable picture: low C15:0 in red blood cell membranes, sometimes alongside elevated ferritin or red cell distribution width.
I'll be honest that "one in three" is an estimate, not a hard population count. But the underlying trend, that our dietary C15:0 has been quietly falling, is well documented and not really in dispute.
What the human trials actually show
The lab science is one thing. What moved me was seeing it hold up in people.
In a randomized controlled trial in young adults with overweight or obesity, 200 mg of C15:0 daily for 12 weeks reliably raised blood levels and was safe and well tolerated [4]. That answers the first question I ask of any supplement: does it actually do anything once you swallow it? It does, and cleanly.
The more interesting signal came from the TANGO trial, which paired a Mediterranean-style diet with C15:0 in people with fatty liver disease. Both diet groups improved, but adding C15:0 produced a further drop in LDL cholesterol and a meaningful bump in a beneficial gut bacterium, Bifidobacterium adolescentis [5]. And in large population studies like EPIC-InterAct, people with naturally higher C15:0 consistently have a lower risk of type 2 diabetes [6].
Is this the final word? No. The decades-long outcome trials simply haven't had time to run. But supplementation raises your levels, higher levels track with better metabolic health, and the safety profile is excellent. For a nutrient that modern diets have stripped out, that's more than enough for me to pay attention.
Why I recommend it (and why I test first)
Fatty15 is the supplement that came out of this research, and it's the one I point patients toward. It's a pure, vegan form of C15:0, 100 mg in a once-daily capsule at about one calorie a dose, without the load of inflammatory even-chain fats you'd take on trying to eat your way to the same number through dairy. And this isn't only for people who avoid butter and whole milk. Because C15:0 is just a trace component of even full-fat dairy, and the amount in our food has quietly dropped over the past few decades, plenty of people who eat perfectly normally still land below optimal. Cutting back on full-fat dairy or eating plant-based foods makes it more likely, but it's far from the only way to come up short — which is why, for most people, it's one of the cleaner, lower-risk additions you can make to a longevity routine.
I'll give you one honest caveat, because I always do: a fair amount of the foundational research comes from the company that makes it. That's not a red flag on its own; the independent trials and population data back it up, but it's exactly why I'd rather not have you guess. I'd rather know your number.
That's the part I love about C15:0. Unlike a lot of what we take, you can actually measure it. A simple finger-stick test tells you whether your levels are low, and a recheck a few months later shows whether supplementing is working. Levels under about 0.2% of your total fatty acids are considered low; the longest-lived populations, like the centenarians of Sardinia, sit closer to 0.64%. I'd much rather build your plan around real data than a hunch.
My take
So here's what I'd suggest. If you're curious where you stand, reach out to me directly. I can order a quick at-home finger-stick test, we'll see your actual C15:0 level, and we'll build from there, whether that's fatty15, a few changes on your plate, or both. You can try fatty15 through the link on our site, and if you'd rather talk it through first, request a consultation. Let's find out your number.
This article is for educational purposes and isn't medical advice. C15:0 supplementation hasn't been evaluated to treat or prevent any disease. Talk with your own provider before adding any supplement, especially if you're pregnant, nursing, or managing a health condition.
References
Venn-Watson S, Lumpkin R, Dennis EA. Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: Could it be essential? Scientific Reports. 2020;10:8161.
Venn-Watson S, Schork NJ. Pentadecanoic Acid (C15:0), an Essential Fatty Acid, Shares Clinically Relevant Cell-Based Activities with Leading Longevity-Enhancing Compounds. Nutrients. 2023;15(21):4607.
Venn-Watson S. The Cellular Stability Hypothesis: Evidence of Ferroptosis and Accelerated Aging-Associated Diseases as a Newly Identified Nutritional Pentadecanoic Acid (C15:0) Deficiency Syndrome. Metabolites.2024;14(7):355.
Robinson MK, Lee E, Ugalde-Nicalo PA, et al. Pentadecanoic Acid Supplementation in Young Adults with Overweight and Obesity: A Randomized Controlled Trial. Journal of Nutrition. 2024;154(9):2763-2771.
Chooi YC, Zhang QA, Magkos F, et al; TANGO Study Group. Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial. American Journal of Clinical Nutrition. 2024;119(3):788-799.
Forouhi NG, Koulman A, Sharp SJ, et al. Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study. Lancet Diabetes & Endocrinology. 2014;2(10):810-818.